# US 2025/0276993 A1 · Pseudo-disaccharide compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0276993 A1
- Document ID: US20250276993A1
- Status: Published application
- Kind: A1
- Application number: 18/858,862
- Filed: 2023-04-28
- Published: 2025-09-04
- Earliest claimed: 2022-04-29
- Assignees: Universiteit Leiden; The University of York
- Applicants: Universiteit Leiden; University of York
- Inventors: Herman OVERKLEEFT; Vincent LIT; Casper DE BOER; Sybrin SCHRÖDER; Gideon DAVIES; Liang WU; Valentina BORLANDELLI
- Web page: https://patentgrep.com/patent/US20250276993A1

## CPC

- C07H 15/207: Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
- A61K 31/336: having three-membered rings, e.g. oxirane, fumagillin
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 31/7056: containing five-membered rings with nitrogen as a ring hetero atom
- A61P 35/00: Antineoplastic agents
- C07D 303/18: by etherified hydroxyl radicals
- C07H 15/26: Acyclic or carbocyclic radicals, substituted by hetero rings
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Provided herein are compounds of formula (I), or a pharmaceutically acceptable salt, solvate, or prodrug thereof: The substituents are as defined herein. Also provided are pharmaceutical compositions comprising the compounds, as well as use of the compounds as a medicament. The compounds or compositions are also useful for inhibiting heparanase (HPSE), for example in the treatment of a condition which is modulated by heparanase. Some compounds may be used for the enzymatic labelling of heparanase.

## Claims

### Claim 1

A compound of formula (I), or a pharmaceutically acceptable salt, solvate, or prodrug thereof:
wherein
X is selected from the group consisting of: —O—, —N(H)—, —N(Ra)—, —N(C(O)Rb)—, —N-L1-fluorophore-, and —N-L1-biotin-;
Y is selected from the group consisting of: —O—, —(CH2)—, and —S—;
R1 is selected from the group consisting of:—H, —OH, —NHC(O)CH3, and —NHSO3−;
R2 is selected from the group consisting of: —H and —SO3−;
R3 is selected from the group consisting of: —H, —OH, —O—C1-6 alkyl, -L2-fluorophore, and -L2-biotin;
R4 is selected from the group consisting of: —H, —OH, —O—C1-6 alkyl and —SO3−;
R5 is selected from the group consisting of: —C(O)O−, —C(O)OC1-6 alkyl, —C(O)NH(C1-6 alkyl), —OPO32−, and —PO32−;
R6 is selected from the group consisting of: —H and —SO3−;
Ra is selected from the group consisting of: C1-6 alkyl and C1-6 alkyl interrupted by one or more ether linkages;
Rb is selected from the group consisting of: C1-6 alkyl and C1-6 alkyl interrupted by one or more ether linkages;
L1 is a linker; and
L2 is a linker,
wherein when X is —N-L1-fluorophore-, or —N-L1-biotin-, R3 is selected from the group consisting of: —H, —OH, and —O—C1-6 alkyl; and
wherein when R3 is -L2-fluorophore, or -L2-biotin, X is selected from the group consisting of: —O—, —N(H)—, —N(Ra)—, and —N(C(O)Rb)—.

### Claim 2 (depends on 1)

The compound of claim 1, wherein X is selected from the group consisting of: —O—, —N(H)—, —N(Ra)—, and —N(C(O)Rb)—; and
wherein R3 is selected from the group consisting of: —H, —OH, and —O—C1-6 alkyl.

### Claim 3 (depends on 1)

The compound of claim 1, wherein X is —O—.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R3 is —OH; and/or
wherein R4 is —OH; and/or
wherein R6 is —H.

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The compound of claim 1, wherein R1 is —NHC(O)Me or —OH.

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The compound of claim 1, wherein Y is —O— or —(CH2)—.

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13 (depends on 1)

The compound of claim 1, wherein -L1-, when present, comprises a —O—C2-24-alkyl or C2-24-alkyl, optionally interrupted by one, two, or three of —NC(O)—, —NH—, —O—, —C(O)—, —C(OH)—, —C(O)O—, and heterocyclic ring system comprising 1,2,3-triazole; and/or wherein -L2-, when present, comprises a —O—C2-24-alkyl or C2-24-alkyl, optionally interrupted by one, two, or three of —NC(O)—, —NH—, —O—, —C(O)—, —C(OH)—, —C(O)O—, and heterocyclic ring system comprising 1,2,3-triazole.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The compound of any of claim 1, wherein
X is —O— and R3 is -L2-fluorophore, or -L2-biotin or
wherein X is —N-L1-fluorophore-, or —N-L1-biotin-, and R3 is OH.

### Claim 16

(canceled)

### Claim 17 (depends on 1)

The compound claim 1, wherein, when present, the fluorophore is selected from the group consisting of cyanine 2, cyanine 3, cyanine 5, BODIPY, fluorescein, and tetramethylrhodamine.

### Claim 18

A compound of formula (XXIVa) or (XXIVb), or a pharmaceutically acceptable salt, solvate, or prodrug thereof:
wherein
X is selected from the group consisting of —O—, —N(H)—, —N(Ra)—, —N(C(O)Rb)—, —N-L1-fluorophore-, and —N-L1-biotin-;
R1 is selected from the group consisting of: —H, —OH, —NHC(O)CH3, and —NHSO3−;
R2 is selected from the group consisting of: —H and —SO3−;
R5 is selected from the group consisting of: —C(O)O—, —C(O)OC1-6 alkyl, —C(O)NH(C1-6 alkyl), —OPO32−, and —PO32−;
R6 is selected from the group consisting of: —H and —SO3−;
R7 is selected from the group consisting of: —H, —C1-6 alkyl, -L3-fluorophore, and -L3-biotin;
Ra is selected from the group consisting of: C1-6 alkyl, and C1-6 alkyl interrupted by one or more ether linkages; and
Rb is selected from C1-6 alkyl, or C1-6 alkyl interrupted by one or more ether linkages;
wherein at least one of R7 and X comprises a fluorophore or a biotin.

### Claim 19 (depends on 18)

The compound of claim 18, wherein R7 is selected from the group consisting of: -L3-fluorophore, and -L3-biotin.

### Claim 20 (depends on 19)

The compound of claim 19, wherein X is selected from the group consisting of: —O—, —N(H)—, —N(Ra)—, and —N(C(O)—Rb).

### Claim 21 (depends on 18)

The compound of claim 18, wherein X is selected from the group consisting of: —N-L1-fluorophore-, and —N-L1-biotin-.

### Claim 22 (depends on 21)

The compound of claim 21, wherein R7 is selected from the group consisting of —H and —C1-6 alkyl.

### Claim 23

(canceled)

### Claim 24 (depends on 18)

The compound of claim 18, wherein -L1-, when present, comprises a C2-24-alkyl, optionally interrupted by one, two, or three of —NC(O)—, —NH—, —O—, —C(O)—, —C(OH)—, —C(O)O—, and heterocyclic ring system comprising 1,2,3-triazole; and/or wherein -L3-, when present, comprises a C2-24-alkyl, optionally interrupted by one, two, or three of —NC(O)—, —NH—, —O—, —C(O)—, —C(OH)—, —C(O)O—, and heterocyclic ring system comprising 1,2,3-triazole.

### Claim 25

(canceled)

### Claim 26 (depends on 1)

The compound of claim 1, wherein the compound is selected from the following, or a pharmaceutically acceptable salt, solvate, or prodrug thereof:

### Claim 27 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1; optionally further comprising a pharmaceutically acceptable excipient.

### Claim 28

(canceled)

### Claim 29

(canceled)

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim 32 (depends on 1)

A method of inhibiting heparanase (HPSE), comprising administration to a cell of an effective amount of a compound of claim 1.

### Claim 33

(canceled)

### Claim 34

(canceled)

### Claim 35 (depends on 1)

A method of treating a condition selected from the group consisting of: cancer, inflammation, inflammatory lung injury, rheumatoid arthritis, chronic colitis, neuroinflammation, sepsis-associated lung injury, inflammatory bowel disease, diabetes, diabetic nephropathy, bone osteolysis, thrombosis, artherosclerosis, inflammatory kidney disease, acute kidney injury, and viral infection (e.g. viral infection caused by herpes simplex virus, dengue virus, human papillomavirus, respiratory syncytial virus, adenovirus, hepatitis C virus, porcine respiratory virus, reproductive syncytial virus, or retroviruses);
the method comprising administering a pharmaceutically effective amount of a compound of claim 1 to a patient in need thereof.

### Claim 36 (depends on 1)

A method of labelling heparanase (HPSE) in vitro or in vivo, the method comprising administering to a cell or a patient an effective amount of a compound of claim 1, wherein said compound comprises a fluorophore or a biotin.
